|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
|
Given how vital the practice is to international regulatory compliance and to keeping products safely on the market, it may be expected that global life sciences firms would have the production and management of patient-facing materials efficiently coordinated so that accuracy and speed to market were taken for granted. Nothing could be further from reality.
Undoubtedly, the global labelling management burden in life sciences has soared in recent years. Companies’ R&D ambitions are growing, businesses are expanding into more markets, and regulators are steadily strengthening safety requirements to protect patients from harm. Each time the benefit/risk profile or safety factors change, or as regional or local regulatory agencies update their standards, international biopharmaceutical firms must react swiftly with accurate, compliant labelling for all affected markets. If they fail to do so, they risk delays to shipping or even to keeping their product registrations on the market, with implications for sales, revenues, and reputation.
Given that all of these market conditions are set to intensify rather than diminish, finding a solution sooner is now a priority. Balancing market opportunity, risk, and cost is becoming increasingly tough to do, so it is unsurprising that organisations are keen to bring the situation under control. As the frequency of changes increases − due to ever-growing product complexity, heightened pharmacovigilance, and new regulatory specifications – the demand soars exponentially.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Infection control has never been more important, let’s use innovation to solve this ongoing issue in our healthcare
In our lifetime, there has rarely been a greater sense of camaraderie
than over the past year. The nation united under a common health threat
and the common good delivered by a National Health Service at their time
of need. In March 2020 the world was forced to stop, readjust, and
overcome the barriers this virus has inflicted upon us all. Whilst it
has sadly been a tragedy for so many businesses, households, and
livelihoods, it has by no means stopped great British ideas, ingenuity,
and innovation. The 5.9 million UK SMEs, which make up 99% of all
business, generating 54% of all UK employment, have demonstrated
remarkable resilience in the face of such adversity, and are at the
forefront of the Government’s Levelling-Up agenda in the post-Covid-19
world that we are all starting to see at the end of the tunnel.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Labelling – More Than Just Labels
Faubel & Co. Nachfolger GmbH
Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >> |
|
|
